Sebaceous Adenoma Follow-up
- Author: Dirk M Elston, MD; Chief Editor: William D James, MD more...
Further Outpatient Care
Completely remove sebaceous adenomas surgically to prevent local recurrences.
Further Inpatient Care
Except for the patients with Muir-Torre syndrome, no inpatient care is recommended for patients with sebaceous adenoma.
Consulting other specialists for patients with suspected Muir-Torre syndrome is recommended to rule out the presence of an occult internal malignancy.
Sebaceous adenomas are benign tumor growths that derive from sebaceous glands. Solitary tumors are treated by complete surgical removal with a 100% cure rate. Incomplete removal has occasionally resulted in local recurrence.
When multiple sebaceous adenomas are associated with Muir-Torre syndrome, visceral carcinomas, including adenocarcinomas of the colon, stomach, duodenum, hematologic system, genitourinary tract, endometrium, and larynx (in decreasing order of frequency) may also be present. The most significant feature of Muir-Torre syndrome is the favorable prognosis of each of the associated carcinomas.
However, some of these malignancies have metastatic potential; deaths due to internal malignancies have been reported. The Mayo clinic has established a scoring system to determine the risk of associated disease. The scoring system includes age at presentation of the initial sebaceous neoplasm, the total number of sebaceous neoplasms, any personal history of a Lynch-related cancer, and family history of Lynch-related cancers. Patients with a score of 3 or more were more likely to have Muir-Torre syndrome.
Advise older patients (>60 y) of the potential existence of an internal malignancy when multiple sebaceous neoplasms are present.
Mehregan AH, Pinkus H. Life history of organoid nevi. Special reference to nevus sebaceus of Jadassohn. Arch Dermatol. 1965 Jun. 91:574-88. [Medline].
Ito K, Sato S, Nishijima A, Hiraga K, Hidano A. Melanogenic melanocytes in human sebaceous glands. Experientia. 1976 Apr 15. 32(4):511-2. [Medline].
Ormsby AH, Snow JL, Su WP, Goellner JR. Diagnostic immunohistochemistry of cutaneous metastatic breast carcinoma: a statistical analysis of the utility of gross cystic disease fluid protein-15 and estrogen receptor protein. J Am Acad Dermatol. 1995 May. 32(5 Pt 1):711-6. [Medline].
Swanson PE. Monoclonal antibodies to human milk fat globule proteins. Wick MR, Siegal GP, eds. Monoclonal antibodies in diagnostic immunohistochemistry. New York, NY: Marcel Dekker; 1988. 227-84.
Bayer-Garner IB, Givens V, Smoller B. Immunohistochemical staining for androgen receptors: a sensitive marker of sebaceous differentiation. Am J Dermatopathol. 1999 Oct. 21(5):426-31. [Medline].
Shikata N, Kurokawa I, Andachi H, Tsubura A. Expression of androgen receptors in skin appendage tumors: an immunohistochemical study. J Cutan Pathol. 1995 Apr. 22(2):149-53. [Medline].
Muir EG, Bell AJ, Barlow KA. Multiple primary carcinomata of the colon, duodenum, and larynx associated with kerato-acanthomata of the face. Br J Surg. 1967 Mar. 54(3):191-5. [Medline].
Torre D. Multiple sebaceous tumors. Arch Dermatol. 1968 Nov. 98(5):549-51. [Medline].
Ollila S, Fitzpatrick R, Sarantaus L, et al. The importance of functional testing in the genetic assessment of Muir-Torre syndrome, a clinical subphenotype of HNPCC. Int J Oncol. 2006 Jan. 28(1):149-53. [Medline].
Rütten A, Burgdorf W, Hugel H, et al. Cystic sebaceous tumors as marker lesions for the Muir-Torre syndrome: a histopathologic and molecular genetic study. Am J Dermatopathol. 1999 Oct. 21(5):405-13. [Medline].
Suspiro A, Fidalgo P, Cravo M, et al. The Muir-Torre syndrome: a rare variant of hereditary nonpolyposis colorectal cancer associated with hMSH2 mutation. Am J Gastroenterol. 1998 Sep. 93(9):1572-4. [Medline].
Marques-da-Costa J, Campos-do-Carmo G, Ormiga P, Ishida C, Cuzzi T, Ramos-E-Silva M. Sebaceous adenoma: clinics, dermatoscopy, and histopathology. Int J Dermatol. 2014 Oct 14. [Medline].
Roberts ME, Riegert-Johnson DL, Thomas BC, Rumilla KM, Thomas CS, Heckman MG, et al. A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome. Genet Med. 2014 Sep. 16(9):711-6. [Medline].
Heyl J, Mehregan D. Immunolabeling pattern of cytokeratin 19 expression may distinguish sebaceous tumors from basal cell carcinomas. J Cutan Pathol. 2008 Jan. 35(1):40-5. [Medline].
Mertens RB, de Peralta-Venturina MN, Balzer BL, Frishberg DP. GATA3 Expression in Normal Skin and in Benign and Malignant Epidermal and Cutaneous Adnexal Neoplasms. Am J Dermatopathol. 2015 Dec. 37 (12):885-91. [Medline].
Smith J, Crowe K, McGaughran J, Robertson T. Sebaceous adenoma arising within an ovarian mature cystic teratoma in Muir-Torre syndrome. Ann Diagn Pathol. 2011 Jun 16. [Medline].
Landis MN, Davis CL, Bellus GA, Wolverton SE. Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy. J Am Acad Dermatol. 2011 Nov. 65(5):1054-1058.e1. [Medline].
Marques-da-Costa J, Campos-do-Carmo G, Ormiga P, Ishida C, Cuzzi T, Ramos-e-Silva M. Sebaceous adenoma: clinics, dermatoscopy, and histopathology. Int J Dermatol. 2015 Jun. 54 (6):e200-2. [Medline].
Misago N, Toda S, Narisawa Y. Two histopathologic patterns of well-differentiated extraocular sebaceous carcinoma. J Cutan Pathol. 2011 Oct. 38(10):767-74. [Medline].
Troy JL, Ackerman AB. Sebaceoma. A distinctive benign neoplasm of adnexal epithelium differentiating toward sebaceous cells. Am J Dermatopathol. 1984 Feb. 6(1):7-13. [Medline].
Sachez Yus E, Requena L, Simon P, del Río E. Sebomatricoma: a unifying term that encompasses all benign neoplasms with sebaceous differentiation. Am J Dermatopathol. 1995 Jun. 17(3):213-21. [Medline].
Svec J, Schwarzová L, Janošíková B, Stekrová J, Mandys V, Kment M, et al. Synchronous gastric and sebaceous cancers, a rare manifestation of MLH1-related Muir-Torre syndrome. Int J Clin Exp Pathol. 2014. 7 (8):5196-202. [Medline].
Roberts ME, Riegert-Johnson DL, Thomas BC, Rumilla KM, Thomas CS, Heckman MG, et al. A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome. Genet Med. 2014 Sep. 16 (9):711-6. [Medline].